4.7 Article

Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 68, 期 25, 页码 2871-2886

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2016.08.079

关键词

dilated cardiomyopathy; genetic testing; genetics; hypertrophic cardiomyopathy; molecular etiology; restrictive cardiomyopathy

资金

  1. Leducq Foundation Transatlantic Networks of Excellence
  2. John S. LaDue Memorial Fellowship at Harvard Medical School
  3. National Institutes of Health (NHLBI) [U10HL110337, NHLBI HL080494, HL084553, U01-HG006500]
  4. Howard Hughes Medical Institutes

向作者/读者索取更多资源

Over the last quarter-century, there has been tremendous progress in genetics research that has defined molecular causes for cardiomyopathies. More than a thousand mutations have been identified in many genes with varying ontologies, therein indicating the diverse molecules and pathways that cause hypertrophic, dilated, restrictive, and arrhythmogenic cardiomyopathies. Translation of this research to the clinic via genetic testing can precisely group affected patients according to molecular etiology, and identify individuals without evidence of disease who are at high risk for developing cardiomyopathy. These advances provide insights into the earliest manifestations of cardiomyopathy and help to define the molecular pathophysiological basis for cardiac remodeling. Although these efforts remain incomplete, new genomic technologies and analytic strategies provide unparalleled opportunities to fully explore the genetic architecture of cardiomyopathies. Such data hold the promise that mutation-specific pathophysiology will uncover novel therapeutic targets, and herald the beginning of precision therapy for cardiomyopathy patients. (C) 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据